254 related articles for article (PubMed ID: 33508971)
1. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
3. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
[TBL] [Abstract][Full Text] [Related]
4. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial.
van Rijssen TJ; van Dijk EHC; Tsonaka R; Feenstra HMA; Dijkman G; Peters PJH; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
Am J Ophthalmol; 2022 Jan; 233():101-110. PubMed ID: 34214454
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
[TBL] [Abstract][Full Text] [Related]
6. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Karasu B; Akbas YB; Aykut A; Celebi ARC
Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
[TBL] [Abstract][Full Text] [Related]
8. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
9. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
10. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
11. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
[TBL] [Abstract][Full Text] [Related]
12. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
Arevalo JF; Espinoza JV
Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
[TBL] [Abstract][Full Text] [Related]
13. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
14. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
Hayashida M; Miki A; Honda S; Nakamura M
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
17. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
[TBL] [Abstract][Full Text] [Related]
18. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.
Park DG; Jeong S; Noh D; Sagong M
Br J Ophthalmol; 2021 Jun; 105(6):844-849. PubMed ID: 32727733
[TBL] [Abstract][Full Text] [Related]
19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.
Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):659-668. PubMed ID: 36202933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
